Literature DB >> 23504671

Enteral or parenteral nimodipine treatment: a comparative pharmacokinetic study.

Christian Scheller1, Andreas Wienke2, Franziska Wurm1, Anne-Sophie Vogel1, Sebastian Simmermacher1, Julian Prell1, Jens Rachinger1, Gershom Koman1, Christian Strauss1, Konstanze Scheller3.   

Abstract

UNLABELLED: BACKGROUND AND STUDY AIMS/OBJECT: Oral nimodipine is recommended to reduce poor outcome related to aneurysmal subarachnoid hemorrhage (SAH). In addition, animal experiments and clinical trails revealed a beneficial effect of enteral and parenteral nimodipine for the regeneration of cranial nerves following skull base, laryngeal, and maxillofacial surgery. Despite these findings there is a lack of pharmacokinetic data in the literature, especially concerning its distribution in nerve tissue. PATIENTS/
MATERIAL AND METHODS: Samples were taken from a consecutive series of 57 patients suffering from skull base lesions and treated with nimodipine prophylaxis from the day before surgery until the seventh postoperative day. Both groups received standard dosages for enteral (n = 25) and parenteral (n = 32) nimodipine . Nimodipine levels were measured in serum, cerebrospinal fluid (CSF), and tissue samples, including vestibular nerves.
RESULTS: Nimodipine levels were significantly higher following parenteral as compared with enteral administration for intraoperative serum (p < 0.001), intraoperative CSF (p < 0.001), tumor tissues (p = 0.01), and postoperative serum (p < 0.001). In addition, nimodipine was significantly more frequently detected in nerve tissue following parenteral administration (Fisher's exact test, p = 0.015).
CONCLUSIONS: From a pharmacokinetic point of view, parenteral nimodipine medication leads to higher levels in serum and CSF. Furthermore, traces are more frequently found in nerve tissue following parenteral as compared with enteral nimodipine administration, at least in the early course. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23504671     DOI: 10.1055/s-0033-1337608

Source DB:  PubMed          Journal:  J Neurol Surg A Cent Eur Neurosurg        ISSN: 2193-6315            Impact factor:   1.268


  2 in total

Review 1.  [Neuroprotective medication in vestibular schwannoma surgery].

Authors:  C Scheller; E Herzfeld; C Strauss
Journal:  HNO       Date:  2017-09       Impact factor: 1.284

2.  Prophylactic nimodipine treatment for hearing preservation after vestibular schwannoma surgery: study protocol of a randomized multi-center phase III trial-AkniPro 2.

Authors:  Christian Scheller; Christian Strauss; Sandra Leisz; Pia Hänel; Ariane Klemm; Simone Kowoll; Iris Böselt; Torsten Rahne; Andreas Wienke
Journal:  Trials       Date:  2021-07-22       Impact factor: 2.279

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.